Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06590493
Status:
AVAILABLE
Last Update Posted:
None
First Post:
2024-09-05
Brief Title:
Doxecitine and Doxribtimine-Expanded Access
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Doxecitine and Doxribtimine-Expanded Access
Status:
AVAILABLE
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Expanded Access Record for doxecitine and doxribtimine includes the following managed access programs
TK0113 Data Collection for Patients in the Company Supported Expanded Access Program Expanded Access Status Available
TK0115 TREATMENT PROTOCOL FOR DOXECITINE AND DOXRIBTIMINE - Company-sponsored Intermediate-size Cohort Expanded Access Program for Doxecitine and Doxribtimine for Patients with Thymidine Kinase 2 Deficiency TK2d with an Age of Symptom Onset 12 Years Expanded Access Status Available
TK0113 Data Collection for Patients in the Company Supported Expanded Access Program Expanded Access Status Available
TK0115 TREATMENT PROTOCOL FOR DOXECITINE AND DOXRIBTIMINE - Company-sponsored Intermediate-size Cohort Expanded Access Program for Doxecitine and Doxribtimine for Patients with Thymidine Kinase 2 Deficiency TK2d with an Age of Symptom Onset 12 Years Expanded Access Status Available
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: